Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : S.Korea to mix-and-match COVID-19 vaccine doses for 760,000 people

06/18/2021 | 03:04am EDT

SEOUL, June 18 (Reuters) - Some 760,000 South Koreans who have received a first dose of AstraZeneca Plc's COVID-19 vaccine will be offered Pfizer Inc's vaccine as a second shot due to shipment delays by global vaccine sharing scheme COVAX, the government said.

Several countries, including Canada and Spain, have already approved such dose-mixing mainly due to concerns about rare and potentially fatal blood clots linked to the AstraZeneca vaccine.

A Spanish study found that giving a dose of the Pfizer shot to people who already received the AstraZeneca vaccine is highly safe and effective, according to preliminary results.

Some 835,000 doses of the AstraZeneca's vaccine from COVAX were scheduled to arrive by the end of June, which South Korea planned to use mainly as a second shot for around 760,000 health and frontline workers who had received their first dose in April.

The shipment is delayed to July or later, while the country had used up available AstraZeneca reserves to meet stronger than expected participation in its vaccination campaign which helped the country meet its first-half inoculation target ahead of schedule.

Over 27% of its 52 million population have been inoculated with at least one dose of a coronavirus vaccine as of Thursday, and the country is on track to meet a target of 70% by September and reach herd immunity before November.

The government expects to receive 80 million doses of COVID-19 vaccines in the third quarter including 10 million in July. They are from AstraZeneca, Pfizer, Johnson & Johnson and Moderna.

South Korea said last month it will conduct a clinical trial that mixes COVID-19 doses from AstraZeneca with those from Pfizer and others.

It has so far run a trial in 100 health workers to examine the formation of antibody and other immune effects, Korea Disease Control and Prevention Agency (KDCA) director Jeong Eun-kyeong told a briefing on Thursday.

South Korea reported 507 new infections by midnight on Thursday, for a tally of 150,238 cases, the KDCA said, with a death toll of 1,996 since the pandemic began. (Reporting by Sangmi Cha; Editing by Miyoung Kim and Raju Gopalakrishnan)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.54% 8315 Delayed Quote.12.97%
MODERNA, INC. -1.98% 346.61 Delayed Quote.231.78%
All news about ASTRAZENECA PLC
08/02Fancy a Covid jab? Here are all the free walk-in sites open in London
08/02ASTRAZENECA : Saphnelo is a first-in-class type I interferon receptor antibody a..
08/02ASTRAZENECA : H1 2021 results - Roadshow and conferences
08/02ASTRAZENECA : Secures US FDA Approval for Saphnelo in Moderate to Severe Systemi..
08/02PFIZER : Malawi Ready to Store, Distribute Incoming Covid-19 Vaccine - Official
08/02AstraZeneca's Saphnelo Approved in U.S. for Moderate-to-Severe SLE
08/02ASTRAZENECA : Lupus Therapy Wins US FDA Approval
08/02ASTRAZENECA : Saphnelo (anifrolumab) approved in the US for moderate to severe s..
08/01MARKET CHATTER : Pfizer, Moderna Raise COVID-19 Vaccine Prices in EU Supply Cont..
08/01CORONAVIRUS : Kenya has Received an Additional 410,000 Doses of AstraZeneca The ..
More news
Financials (USD)
Sales 2021 35 065 M - -
Net income 2021 5 236 M - -
Net Debt 2021 25 946 M - -
P/E ratio 2021 30,4x
Yield 2021 2,45%
Capitalization 178 B 178 B -
EV / Sales 2021 5,82x
EV / Sales 2022 4,74x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 114,93 $
Average target price 133,86 $
Spread / Average Target 16,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC12.97%178 150
JOHNSON & JOHNSON9.46%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.19.42%239 637
NOVARTIS AG0.28%225 343